Thymosin Alpha-1
Reported Onset
2–4 weeks
Primary Use
Immune system modulation, T-cell function enhancement, and antiviral support.
Dose
1.6mg
Frequency
2x weekly
LL-37
Reported Onset
2–4 weeks
Primary Use
Antimicrobial action, wound healing, and innate immune activation.
Dose
100mcg - 500mcg
Frequency
Daily or as per wound protocol
Community Verdict
Antimicrobial vs immune modulation — innate vs adaptive immunity. The community generally selects between Thymosin Alpha-1 and LL-37 based on their specific goals and experience. Both compounds are available through physician-supervised protocols at Alukard, where a physician can help determine which is most appropriate for your situation.
Get a Physician-Supervised Protocol for Thymosin Alpha-1 or LL-37 at Alukard
Community experiences are a starting point — but a physician-supervised protocol from Alukard gives you pharmaceutical-grade compounds, proper dosing, lab monitoring, and the safety of medical oversight.
MD
Supervised
GMP
Certified
Labs
Monitoring
COA
Verified